Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Atezolizumab for Pulmonary Fibrosis
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing atezolizumab, a medicine that boosts the immune system, in people aged 50 to 80 with idiopathic pulmonary fibrosis (IPF). IPF is a lung disease with no current treatments to stop its progression. Atezolizumab may help slow down lung damage by helping the immune system fight the disease.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service